Plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation

被引:11
|
作者
Furuya, Maiko [1 ]
Yamamoto, Izumi [1 ]
Kobayashi, Akimitsu [1 ]
Nakada, Yasuyuki [1 ]
Sugano, Naoki [1 ]
Tanno, Yudo [1 ]
Ohkido, Ichiro [1 ]
Tsuboi, Nobuo [1 ]
Yamamoto, Hiroyasu [2 ]
Yokoyama, Keitaro [1 ]
Yokoo, Takashi [1 ]
机构
[1] Jikei Univ, Div Nephrol & Hypertens, Dept Internal Med, Sch Med, Tokyo 1058471, Japan
[2] Atsugi City Hosp, Dept Internal Med, Atsugi, Kanagawa, Japan
关键词
acute antibody-mediated rejection; anti-DQ antibody; plasma cell-rich rejection; RISK; HLA;
D O I
10.1111/nep.12245
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We report a case of plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation. A 33-year-old man was admitted for an episode biopsy; he had a serum creatinine (S-Cr) level of 5.7mg/dL 1 year following primary kidney transplantation. Histological features included two distinct entities: (1) a focal, aggressive tubulointerstitial inflammatory cell (predominantly plasma cells) infiltration with moderate tubulitis; and (2) inflammatory cell infiltration (including neutrophils) in peritubular capillaries. Substantial laboratory examination showed that the patient had donor-specific antibodies for DQ4 and DQ6. Considering both the histological and laboratory findings, we diagnosed him with plasma cell-rich rejection accompanied by acute antibody-mediated rejection. We started 3 days of consecutive steroid pulse therapy three times every 2 weeks for the former and plasma exchange with intravenous immunoglobulin (IVIG) for the latter histological feature. One month after treatment, a second allograft biopsy showed excellent responses to treatment for plasma cell-rich rejection, but moderate, acute antibody-mediated rejection remained. Therefore, we added plasma exchange with IVIG again. After treatment, allograft function was stable, with an S-Cr level of 2.8mg/dL. This case report demonstrates the difficulty of the diagnosis of, and treatment for, plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation. We also include a review of the related literature.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 50 条
  • [1] Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation
    Yanagi, Yusuke
    Sakamoto, Seisuke
    Yamada, Masaki
    Mimori, Koutaro
    Nakao, Toshimasa
    Kodama, Tasuku
    Uchida, Hajime
    Shimizu, Seiichi
    Fukuda, Akinari
    Nakano, Noriyuki
    Haga, Chiduko
    Yoshioka, Takako
    Kasahara, Mureo
    [J]. TRANSPLANTATION DIRECT, 2022, 8 (09): : E1359
  • [2] Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation
    Spica, Davide
    Junker, Till
    Dickenmann, Michael
    Schaub, Stefan
    Steiger, Jurg
    Rufli, Tanja
    Halter, Jorg
    Hopfer, Helmut
    Holbro, Andreas
    Hirt-Minkowski, Patricia
    [J]. SWISS MEDICAL WEEKLY, 2019, : 14S - 15S
  • [3] Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
    Spica, Davide
    Junker, Till
    Dickenmann, Michael
    Schaub, Stefan
    Steiger, Jurg
    Rufli, Tanja
    Halter, Jorg
    Hopfer, Helmut
    Holbro, Andreas
    Hirt-Minkowski, Patricia
    [J]. CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2019, 9 (03): : 149 - 157
  • [4] REVERSAL OF REFRACTORY ANTIBODY-MEDIATED REJECTION IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION BY ECULIZUMAB
    Morath, C.
    Kirschfink, M.
    Waldherr, R.
    Becker, L. E.
    Kihm, L. P.
    Schaier, M.
    Schwenger, V.
    Schmidt, J.
    Hohenfellner, M.
    Leo, A.
    Opelz, G.
    Suesal, C.
    Zeier, M.
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 34 - 34
  • [5] Subclinical antibody-mediated rejection due to anti-human-leukocyteantigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation
    Katsuma, Ai
    Yamamoto, Izumi
    Komatsuzaki, Yo
    Niikura, Takahito
    Kawabe, Mayuko
    Okabayashi, Yusuke
    Yamakawa, Takafumi
    Katsumata, Haruki
    Nakada, Yasuyuki
    Kobayashi, Akimitsu
    Tanno, Yudo
    Miki, Jun
    Yamada, Hiroki
    Ohkido, Ichiro
    Tsuboi, Nobuo
    Yamamoto, Hiroyasu
    Yokoo, Takashi
    [J]. NEPHROLOGY, 2016, 21 : 31 - 34
  • [6] ABO Antibody Titer and Risk of Antibody-Mediated Rejection in ABO-Incompatible Renal Transplantation
    Tobian, A. A. R.
    Shirey, R. S.
    Montgomery, R. A.
    Cai, W.
    Haas, M.
    Ness, P. M.
    King, K. E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1247 - 1253
  • [7] The Significance of Microvascular Inflammation in Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.
    Ishihara, H.
    Ishida, H.
    Unagami, K.
    Hirai, T.
    Okumi, M.
    Omoto, K.
    Shimizu, T.
    Tanabe, K.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 601 - 602
  • [8] Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation
    Maenosono, Ryoichi
    Unagami, Kohei
    Kakuta, Yoichi
    Furusawa, Miyuki
    Okumi, Masayoshi
    Azuma, Haruhito
    Ishida, Hideki
    Tanabe, Kazunari
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (12) : 1114 - 1120
  • [9] Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption
    Just, Soren Andreas
    Marcussen, Niels
    Sprogoe, Ulrik
    Koefoed-Nielsen, Pernille
    Bistrup, Claus
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (01) : 310 - 313
  • [10] Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
    Kakuta, Y.
    Okumi, M.
    Kanzawa, T.
    Unagami, K.
    Ishida, H.
    Tanabe, K.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 898 - 898